1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xbrane Biopharma AB (publ)
  6. News
  7. Summary
    XBRANE   SE0007789409

XBRANE BIOPHARMA AB (PUBL)

(XBRANE)
  Report
Delayed Nasdaq Stockholm  -  05/25 06:59:34 am EDT
74.70 SEK   +0.40%
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Xbrane Biopharma moves to Nasdaq Stockholm Mid Cap segment

12/20/2021 | 07:56am EDT

Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE), a leading biosimilar developer, has announced that the company’s shares will be moved to Nasdaq Stockholm’s Mid Cap segment on January 3rd, 2022.

The move from the Small Cap segment is a result of Nasdaq’s annual review of the average market values within the Nordic market segments. The Mid Cap segment includes companies with a share value between EUR 150 million and EUR 1 billion. The move was announced by Nasdaq Stockholm on December 20th, 2021. The company is now taking the step from the Small Cap to the Mid Cap segment after a strong price trend during the year.

© Modular Finance, source Nordic Press Releases

All news about XBRANE BIOPHARMA AB (PUBL)
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/05Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Invitation to presentation of Xbrane Biopharma's interim report January – March 2..
AQ
04/05Correction regarding notice of annual general meeting in Xbrane Biopharma
AQ
04/04Notice of annual general meeting in Xbrane Biopharma AB
AQ
03/31Xbrane Biopharma releases annual report 2021
AQ
03/09Xbrane Biopharma - Xciting and Increasingly Compelling Case
AQ
02/24TRANSCRIPT : Xbrane Biopharma AB, Q4 2021 Earnings Call, Feb 24, 2022
CI
More news
Financials
Sales 2021 18,7 M 1,90 M 1,90 M
Net income 2021 -225 M -22,8 M -22,8 M
Net cash 2021 445 M 45,1 M 45,1 M
P/E ratio 2021 -7,60x
Yield 2021 -
Capitalization 1 870 M 189 M 189 M
EV / Sales 2021 76,1x
EV / Sales 2022 5,19x
Nbr of Employees 64
Free-Float 66,3%
Chart XBRANE BIOPHARMA AB (PUBL)
Duration : Period :
Xbrane Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XBRANE BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 74,70 SEK
Average target price 235,00 SEK
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Martin ┼mark Chief Executive Officer
Anette Lindqvist Chief Financial Officer & Head-Investor Relations
Anders Lennart Tullgren Chairman
David Vikstr÷m Chief Technology Officer
Siavash Bashiri Chief Operating Officer & Head-Biosimilars
Sector and Competitors
1st jan.Capi. (M$)
XBRANE BIOPHARMA AB (PUBL)-29.01%190
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581